Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00557492 |
Recruitment Status
:
Active, not recruiting
First Posted
: November 14, 2007
Results First Posted
: December 12, 2016
Last Update Posted
: July 7, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Cancer | Drug: Avastin (bevacizumab) Drug: Gemzar (Gemcitabine) Radiation: external beam radiotherapy | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 59 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Study of the Anti-Vascular Endothelial Growth Factor (α-VEGF) Monoclonal Antibody Bevacizumab in Combination With Fixed Dose Rate (FDR) Gemcitabine and Rapid-Fractionation Radiotherapy in the Pre-operative Treatment of Potentially- Resectable Pancreatic Adenocarcinoma |
Study Start Date : | December 2006 |
Actual Primary Completion Date : | March 2012 |
Estimated Study Completion Date : | December 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Single Arm
Intervention: Drug: Avastin (bevacizumab) 10 mg/kg, days 1, 15, 29 and 43 Intervention: Drug: Gemzar (Gemcitabine) On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min). Intervention:Radiation: external beam radiotherapy 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy |
Drug: Avastin (bevacizumab)
10 mg/kg, days 1, 15, 29 and 43
Drug: Gemzar (Gemcitabine)
On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
Radiation: external beam radiotherapy
3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
|
- Rate of Margin Negative Surgical Resection (R0 Resection Rate) [ Time Frame: Up to 48 months ]Number of participants who underwent laparoscopy and pancreatic resections that were margin negative/total number of participants who underwent laparoscopy and pancreatic resections.
- Rate of Pathologic Complete Response (pCR) [ Time Frame: Up to 48 months ]Rate of pathologic complete response (pCR) is no residual invasive tumor, in situ carcinoma can be present, and no residual lymph node metastasis. Rate of pCR is the number of participants who underwent laparoscopy and pancreatic resections that experienced complete pathologic response/total number of participants who underwent laparoscopy and pancreatic resections.
- Overall Survival (OS) [ Time Frame: Up to 48 months ]
- Progression-free Survival (PFS) [ Time Frame: Up to 48 months ]
- Rate of Surgical Resection [ Time Frame: Up to 48 months ]Number of participants that underwent resection / per the total number of evaluable participants
- Radiographic Tumor Response [ Time Frame: Up to 48 months ]CT scans evaluated for response using Response Evaluation Criteria in Solid Tumors (RECIST)
- Ca 19-9 Level (in Serum) - Biomarker Response [ Time Frame: Baseline and up to 48 months ]Percentage decrease in Ca 19-9 level (in serum)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologic or cytologic proof of pancreatic adenocarcinoma.
- Subjects with biopsy-proven adenocarcinoma of the pancreas which is potentially resectable by preoperative imaging. Subjects will be considered potentially resectable using criteria defined by Pisters (Pisters et al., 2001):
- if imaging detects no evidence of extrapancreatic disease;
- no evidence of tumor extension to the superior mesenteric artery (SMA) or celiac axis (intact fat plane between the tumor and the adjacent visceral artery),
- patent superior mesenteric-portal vein confluence
- no encasement of portal or superior mesenteric vein.
- Karnofsky performance status ≥ 80.
- No active second malignancy except for basal cell carcinoma of the skin
- Normal renal, hepatic, and hematologic function at the time of enrollment as evidenced by:
- Serum creatinine level ≤1.6 mg/dl ( Calculated Creat clearance >50)
- Serum total bilirubin level ≤1.5 X ULN
- Urine protein excretion ≤ 1+ by urine dipstick
- White blood cell count ≥ 3.5x109/ml per ml and platelet count ≥ 100x109 per ml
- Age >18 years.
- Children are excluded because of toxic effects of bevacizumab and gemcitabine on growth and development during preclinical studies.
- For subjects with obstructive jaundice, the biliary tract must be drained with a temporary plastic or a short permanent metallic biliary stent.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Disease-Specific Exclusions
- Subjects who have received chemotherapy within 12 months prior to study entry.
- Prior use of radiotherapy or investigational agents for pancreatic cancer.
- Subjects who have undergone laparotomy for pancreas cancer within 6 weeks
- Any evidence of metastasis to distant organs (liver, lung, peritoneum).
-
Symptomatic or endoscopic evidence of gastric outlet obstruction
• Endoscopic findings suggesting tumor erosion into the gastrointestinal mucosa.
- Concurrent malignancies with evidence of active or measurable disease except basal cell carcinoma of the skin.
- General Medical Exclusions
- Inability to adhere to study and/or follow-up procedures
- History of allergic reactions or hypersensitivity to the study drugs (bevacizumab, gemcitabine, and proton pump inhibitors).
- Other concurrent experimental therapy.
- Because subjects with immune deficiency are at increased risk for lethal infections when treated with marrow-suppressive therapy, HIV-positive subjects receiving combination anti-retroviral therapy are excluded from the study.
- Bevacizumab-Specific Exclusions
- Subjects who have had recent surgery (prior 6 weeks)
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
- Subjects with the following co-morbid medical conditions:
- History of myocardial infarction or unstable angina within 12 months prior to study enrollment.
- Ascites
- Pregnancy/lactation - The effects of the study drugs on the developing human fetus are unknown. For this reason and because bevacizumab, gemcitabine, and radiation therapy used in this trial are known to be teratogenic in animal studies, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of study entry until 6 months after the completion of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A serum pregnancy test for those females of childbearing potential must be done prior to their receiving study drugs. Due to the combined effects of chemotherapy and radiation, breastfeeding is not allowed for 6 months after the completion of study participation.
- Regular aspirin use > 325 mg per day
- Regular NSAID use
- Bleeding diathesis, coagulopathy, need for full-dose anticoagulation or INR > 1.5
- Known central nervous system metastasis
- Previous cerebrovascular accident, transient ischemic attack, or seizure (within 6 months)
- Serious non-healing wound, ulcer, or bone fracture
- History of abdominal fistula, gastrointestinal perforation, diverticulitis, or intra-abdominal abscess within 6 months prior to study enrollment.
- Recent hemoptysis,
- Uncontrolled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)
- Any prior history of hypertensive crisis or hypertensive encephalopathy
- New York Heart Association (NYHA) grade 2 or greater congestive heart failure (see Appendix I)
- Prior deep venous thrombosis or pulmonary embolism
- Urine protein excretion 2+ or ≥ 1 g per 24 hours
- Peripheral vascular disease such as lower extremity claudication and rest pain or prior lower extremity vascular surgery for arterial insufficiency
- Dyspnea requiring supplemental oxygen

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00557492
United States, Pennsylvania | |
University of Pittsburgh Medical Centers | |
Pittsburgh, Pennsylvania, United States, 15232 |
Principal Investigator: | Herbert J. Zeh, MD | University of Pittsburgh |
Responsible Party: | Herbert J. Zeh, III MD, FACS, Associate Professor of Medicine, University of Pittsburgh, University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT00557492 History of Changes |
Obsolete Identifiers: | NCT00428324 |
Other Study ID Numbers: |
06-035 |
First Posted: | November 14, 2007 Key Record Dates |
Results First Posted: | December 12, 2016 |
Last Update Posted: | July 7, 2017 |
Last Verified: | June 2017 |
Keywords provided by Herbert J. Zeh, III MD, FACS, University of Pittsburgh:
pancreas pancreatic cancer resectable |
Additional relevant MeSH terms:
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Gemcitabine Bevacizumab Endothelial Growth Factors Antimetabolites, Antineoplastic Antimetabolites |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Growth Inhibitors |